Change over period
From:
To:
Zoom:
- 3M
- 6M
- YTD
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
DiaMedica Therapeutics Inc
NASDAQ DMAC
Data sourced from
and
and
Download Data
DiaMedica Therapeutics Inc Share Price on June 03, 2024: USD 2.95
DiaMedica Therapeutics Inc Share Price is USD 2.95 on June 03, 2024, a 9.26% change year over year. Share price refers to the current trading price of a single share of a company's stock. It represents the monetary value that investors are willing to pay for ownership in the company. Share prices are determined by the supply and demand dynamics in the stock market and can fluctuate throughout the trading day. Changes in share prices are influenced by various factors, including company performance, industry trends, market conditions, investor sentiment, and economic indicators. Share price is a key indicator used by investors to assess the performance and valuation of a company's stock.
-
DiaMedica Therapeutics Inc 52-week high Share Price is USD 4.40 on July 03, 2023, which is 49.15% above the current Share Price.
-
DiaMedica Therapeutics Inc 52-week low Share Price is USD 2.05 on October 13, 2023, which is -30.51% below the current Share Price.
-
DiaMedica Therapeutics Inc average Share Price for the last 52 weeks is USD 2.91.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: DMAC
| CEO | Mr. Dietrich John Pauls MBA |
| IPO Date | Jan. 4, 2008 |
| Location | United States |
| Headquarters | Two Carlson Parkway, Minneapolis, MN, United States, 55447 |
| Employees | 18 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Key trends
Similar companies
Milestone Pharmaceuticals Inc
NA
NA
Centessa Pharmaceuticals PLC ADR
NA
NA
Day One Biopharmaceuticals Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email